Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
May 15 ANRO Alto Neuroscience reports Q1 GAAP EPS of -$0.76
May 15 RVPH Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
May 14 OMER Omeros Q1 2024 Earnings Preview
May 14 ANRO Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14 RVPH Reviva Pharmaceuticals GAAP EPS of -$0.25
May 14 RVPH Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14 ALKS Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
May 14 AZN PRESS DIGEST-British Business - May 14
May 13 JAZZ Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
May 13 BMY Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
May 13 AZN UK pharma giants pledge £430m investment in France after Macron charm offensive
May 13 AZN AstraZeneca, Pfizer to invest combined $900M+ in France for R&D, production
May 13 AZN Update: AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study
May 13 BMY One stock is dragging down the S&P 500's earnings growth
May 13 BMY BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
May 13 AZN Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13 AZN Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
May 13 BMY Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
May 13 BMY These Stocks Are Moving the Most Today: GameStop, AMC, Arm, Squarespace, Tesla, Intel, Apple, Incyte, and More
May 13 AZN France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags